心脏生物标志物对2型心肌梗死的预测、鉴别和风险分层：一个关键的评估。

IF 2.5 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

American Journal of Medicine Pub Date : 2025-04-26 DOI:10.1016/j.amjmed.2025.04.024

Daniel L Pollmann, Jonathan D Knott, Pedro E P Carvalho, Fred S Apple, Allan S Jaffe, Yader Sandoval

{"title":"心脏生物标志物对2型心肌梗死的预测、鉴别和风险分层：一个关键的评估。","authors":"Daniel L Pollmann, Jonathan D Knott, Pedro E P Carvalho, Fred S Apple, Allan S Jaffe, Yader Sandoval","doi":"10.1016/j.amjmed.2025.04.024","DOIUrl":null,"url":null,"abstract":"Distinguishing between myocardial infarction caused by atherothrombotic (type 1) and non-atherothrombotic (type 2) etiologies is a frequently encountered and clinically important distinction. This review provides a critical appraisal of studies addressing the use of cardiac biomarkers in type 2 myocardial infarction for a) discrimination, b) prediction, and c) risk-stratification. No single biomarker thus far provides robust performance for these purposes. There are efforts, however, at combining multiple biomarkers in stepwise models with or without additional clinical features, as well as novel biomarker approaches to improve performance.","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardiac Biomarkers for the Prediction, Discrimination, and Risk-Stratification of Type 2 Myocardial Infarction: A Critical Appraisal.\",\"authors\":\"Daniel L Pollmann, Jonathan D Knott, Pedro E P Carvalho, Fred S Apple, Allan S Jaffe, Yader Sandoval\",\"doi\":\"10.1016/j.amjmed.2025.04.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Distinguishing between myocardial infarction caused by atherothrombotic (type 1) and non-atherothrombotic (type 2) etiologies is a frequently encountered and clinically important distinction. This review provides a critical appraisal of studies addressing the use of cardiac biomarkers in type 2 myocardial infarction for a) discrimination, b) prediction, and c) risk-stratification. No single biomarker thus far provides robust performance for these purposes. There are efforts, however, at combining multiple biomarkers in stepwise models with or without additional clinical features, as well as novel biomarker approaches to improve performance.\",\"PeriodicalId\":50807,\"journal\":{\"name\":\"American Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjmed.2025.04.024\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjmed.2025.04.024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

区分由动脉粥样硬化性血栓（1型）和非动脉粥样硬化性血栓（2型） 病因引起的心肌梗死 是一个经常遇到的和临床上重要的区分。本综述对在2型心肌梗死中使用心脏生物标志物的研究进行了批判性评价，包括(a)区分、(b)预测和(c)风险分层。到目前为止，还没有一种单一的生物标志物能在这些方面提供可靠的性能。然而，人们正在努力将多种生物标志物结合到逐步模型中，有或没有额外的临床特征，以及新的生物标志物方法来提高性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cardiac Biomarkers for the Prediction, Discrimination, and Risk-Stratification of Type 2 Myocardial Infarction: A Critical Appraisal.

Distinguishing between myocardial infarction caused by atherothrombotic (type 1) and non-atherothrombotic (type 2) etiologies is a frequently encountered and clinically important distinction. This review provides a critical appraisal of studies addressing the use of cardiac biomarkers in type 2 myocardial infarction for a) discrimination, b) prediction, and c) risk-stratification. No single biomarker thus far provides robust performance for these purposes. There are efforts, however, at combining multiple biomarkers in stepwise models with or without additional clinical features, as well as novel biomarker approaches to improve performance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Medicine 医学-医学：内科

CiteScore

6.30

自引率

3.40%

发文量

449

审稿时长

9 days

期刊介绍： The American Journal of Medicine - "The Green Journal" - publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. AJM is the official journal of the Alliance for Academic Internal Medicine, a prestigious group comprising internal medicine department chairs at more than 125 medical schools across the U.S. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance and position papers on health care issues, medical education, and public policy.